Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesTransplantAmbetter Nevada pediatric kidney transplant Covera…
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy CP.MP.246

    Pediatric Kidney Transplant Coverage Criteria

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.MP.246 alerts

    Get alerted when Policy CP.MP.246 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria for pediatric kidney transplantation for non-Medicare health plans affiliated with Centene (pediatric members <18), including indications, contraindications, and coding references.

    Policy Summary
    PayerAmbetter Nevada
    PolicyPediatric Kidney Transplant Coverage Criteria
    Policy CodePolicy CP.MP.246
    Change TypeCriteria revision (GFR thresholdscontraindication clarifications)
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and submit clinical documentation demonstrating ESRD (GFR < 15) or CKD stage 4 (GFR < 30 if expected to reach ESRD) and absence of listed contraindications.
    SourceLink
    POLICY UPDATE CHANGES

    Changed GFR threshold for ESRD criterion from ≤ 15 mL/min/1.73m2 to < 15 mL/min/1.73m2 to align with KDIGO and OPTN guidance.

    Expanded stage 4 CKD criterion to include members with GFR < 30 mL/min/1.73m2 who are expected to reach end-stage renal disease (ESRD).

    Updated contraindications (I.B) to be consistent with KDIGO guideline recommendations, including detailed HIV criteria (CD4, absence of opportunistic infection, on ART).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Age < 18Population covered (pediatric members)
    GFR < 15ESRD threshold for transplant eligibility
    GFR < 30CKD stage 4 threshold
    10 itemsContraindication categories
    Multiple codesCoding guidance included

    Transplant Coverage Criteria

    Initial transplant eligibility

    Covered when ALL of the following are met:

    Overall

    • A. Advanced renal disease: Member has one of: (1) End-stage renal disease (ESRD, stage 5) with GFR < 15 mL/min/1.73 m2; OR (2) Chronic kidney disease (CKD, stage 4) with GFR < 30 mL/min/1.73 m2 in members expected to reach ESRD.GFR thresholds as specified

      Patients with GFR > 30 who are rapidly progressing toward ESRD should be referred for evaluation.

    • B. Contraindications absent

      • Contraindications list: 1. Active infection that is not properly treated (except hepatitis C); 2. HIV infection with detectable viral load unless all of the following are documented: a) CD4 > 200 cells/mm3; b) absence of active AIDS-defining opportunistic infection; c) currently on effective antiretroviral therapy (ART); 3. Active malignancy with high risk of recurrence or death related to cancer; 4. Stroke within the past 6 months or transient ischemic attack within the past 3 months; 5. Active symptomatic cardiac disease (e.g., angina, arrhythmia, heart failure, valvular disease) that has not been evaluated by a cardiologist — cardiology clearance required after myocardial infarction; 6. Active symptomatic peripheral arterial disease not properly managed; 7. Inability to adhere to the regimen necessary to preserve the transplant, even with caregiver support; 8. Active or ongoing substance use disorder that affects decision-making or increases post-transplant risk; 9. Decompensated cirrhosis unless candidate for combined liver–kidney transplant; 10. Elevated circulating anti-glomerular basement membrane (anti-GBM) antibodies.See individual items for specific timeframes and lab cutoffs

        Refer to policy for HIV-specific documentation and exceptions for hepatitis C.

    Operational note: Prior authorization is required and clinical documentation must demonstrate the advanced renal disease criteria and absence (or remediation) of listed contraindications; HIV-positive candidates must document CD4 > 200 cells/mm3, absence of active AIDS-defining infection, and current effective ART.

    See coding and prior authorization guidance for CPT/HCPCS codes to include in requests.

    Coverage for pediatric kidney transplantation is excluded while the member has unresolved contraindications as listed in this policy. Key exclusions include active infection that is not properly treated (except hepatitis C), active malignancy with high risk of recurrence or death, recent cerebrovascular events (stroke within 6 months or TIA within 3 months), active symptomatic cardiac or peripheral arterial disease that has not been appropriately evaluated or managed, inability to adhere to the required post‑transplant regimen despite caregiver support, active substance use disorder that increases post‑transplant risk, decompensated cirrhosis unless the candidate is being considered for combined liver‑kidney transplant, and elevated circulating anti‑glomerular basement membrane antibodies.

    Transplantation is not medically necessary when any of the explicit contraindications are present and cannot be remedied. Examples that will trigger denial include active untreated infection (except hepatitis C), HIV with detectable viral load without documented clearance criteria, active malignancy with high recurrence or mortality risk, recent stroke or TIA within the specified timeframes, active symptomatic cardiac disease without cardiology evaluation or clearance after myocardial infarction, unmanaged peripheral arterial disease, inability to adhere to the required regimen, ongoing substance use disorder that impairs decision‑making or increases post‑transplant risk, decompensated cirrhosis when not a combined‑organ candidate, and markedly elevated anti‑GBM antibodies.

    Candidate Selection and Eligibility

    Candidate selection — disease severity and contraindications

    Candidate meets transplant eligibility when all disease severity and absence-of-contraindication criteria are met.

    Candidate criteria

    • Disease severity: ESRD (stage 5) with GFR < 15 mL/min/1.73 m2 OR CKD (stage 4) with GFR < 30 mL/min/1.73 m2 in members expected to reach ESRD.GFR thresholds as specified

      Rapidly progressing patients with GFR > 30 should be referred for evaluation.

    • Absence of contraindications

      • Listed contraindications: 1) Active untreated infection (except HCV); 2) HIV with detectable viral load unless CD4 > 200 cells/mm3, absence of active AIDS-defining opportunistic infection, and on effective ART; 3) Active malignancy with high risk of recurrence or death; 4) Stroke within past 6 months or TIA within past 3 months; 5) Active symptomatic cardiac disease not evaluated by cardiology (cardiology clearance required after MI); 6) Active symptomatic peripheral arterial disease not properly managed; 7) Inability to adhere to required regimen despite caregiver support; 8) Active/ongoing substance use disorder affecting decision-making or increasing post-transplant risk; 9) Decompensated cirrhosis unless candidate for combined liver–kidney transplant; 10) Elevated circulating anti-GBM antibodies.

    Contraindications and Exclusions

    Detailed contraindications that must be absent or resolved prior to listing or transplantation include: active infection that is not properly treated (except hepatitis C); HIV infection with detectable viral load unless all three of the following are documented: CD4 cell count > 200 cells/mm3, absence of active AIDS‑defining opportunistic infection, and the member is currently on effective antiretroviral therapy (ART); active malignancy with high risk of recurrence or death; stroke within the past 6 months or transient ischemic attack within the past 3 months; active symptomatic cardiac disease (e.g., angina, arrhythmia, heart failure, valvular disease) that has not been evaluated by a cardiologist — and cardiology clearance is required after myocardial infarction; active symptomatic peripheral arterial disease that is not properly managed; inability to adhere to the regimen necessary to preserve the transplant even with caregiver support; active or ongoing substance use disorder that affects decision‑making or increases post‑transplant risk; decompensated cirrhosis unless the candidate is being considered for a combined liver‑kidney transplant; and elevated circulating anti‑glomerular basement membrane antibodies.

    Pre-Transplant Evaluation Requirements

    Prior Authorization

    Multidisciplinary evaluation and cardiac assessment required

    Perform a multidisciplinary transplant evaluation consistent with KDIGO and OPTN guidance; determine the cause of ESRD when possible and obtain cardiology evaluation for symptomatic cardiac disease or cardiology clearance after myocardial infarction.

    • Multidisciplinary evaluation per KDIGO and OPTN guidance.
    • Determine cause of ESRD where possible.
    • Cardiology evaluation for symptomatic cardiac disease; cardiology clearance required after MI.

    Provider Actions and Prior Authorization

    Prior Authorization

    Prior authorization required; cite procedure codes

    Request prior authorization per payer procedures for pediatric kidney transplantation and reference the listed CPT and HCPCS codes when submitting requests.

    • Include relevant clinical evidence demonstrating medical necessity with the PA request.
    • Reference procedure codes such as 50300, 50320, 50323, 50325, 50327, 50328, 50329, 50360, 50365, 50547, and S2152 as applicable.
    Step Therapy

    No step therapy required

    No step therapy requirements are specified in this policy; evaluation and coverage determination are based on meeting transplant medical necessity criteria and guideline-based evaluation.

    Documentation Required

    Coding and Billing References (Informational)

    Referenced procedure codes (informational)CPT | HCPCS
    50300Donor nephrectomy (including cold preservation); from cadaver donor, unilateral or bilateral.
    50320Donor nephrectomy (including cold preservation); open, from living donor.
    50323Backbench standard preparation of cadaver donor renal allograft prior to transplantation, including dissection and removal of perinephric fat, diaphragmatic and retroperitoneal attachments, excision of adrenal gland, and preparation of ureter(s), renal vein(s), and renal artery(s), ligating branches, as necessary.
    50325Backbench standard preparation of living donor renal allograft (open or laparoscopic) prior to transplantation, including dissection and removal of perinephric fat and preparation of ureter(s), renal vein(s), and renal artery(s), ligating branches, as necessary.
    50327Backbench reconstruction of cadaver or living donor renal allograft prior to transplantation; venous anastomosis, each.
    50328Backbench reconstruction of cadaver or living donor renal allograft prior to transplantation; arterial anastomosis, each.
    50329Backbench reconstruction of cadaver or living donor renal allograft prior to transplantation; ureteral anastomosis, each.
    50360Renal allotransplantation, implantation of graft; without recipient nephrectomy.
    50365Renal allotransplantation, implantation of graft; with recipient nephrectomy.
    50547Laparoscopy, surgical; donor nephrectomy (including cold preservation), from living donor.
    1–10 of 11
    1/2
    GFR thresholds — ESRD and CKD stage 4
    ESRD (stage 5) thresholdGFR < 15 mL/min/1.73m2
    CKD stage 4 threshold (eligible if expected to progress)GFR < 30 mL/min/1.73m2 when expected to reach ESRD
    Rapidly progressing patients referral notePatients with GFR > 30 mL/min/1.73m2 who are rapidly progressing toward ESRD should be referred for transplant evaluation

    Definitions and Thresholds

    ESRD (stage 5) — definition
    Definition (ESRD, stage 5)End-stage renal disease defined as GFR < 15 mL/min/1.73m2
    PopulationApplies to pediatric members/enrollees (age < 18)
    Use in eligibility determinationMeets the advanced renal disease criterion for transplant candidacy when documented in clinical record
    CKD stage 4 — eligibility criterion
    CKD stage 4 numeric thresholdGFR < 30 mL/min/1.73m2
    Eligibility conditionEligible for transplant evaluation if expected to reach ESRD
    Referral note

    Center and Program Requirements

    Note

    Center must follow guideline-based evaluation; no explicit accreditation listed

    Policy references guideline-based center evaluation but does not specify explicit center accreditation, minimum volume, or other institutional requirements in this document.

    • Follow guideline-based evaluation processes (KDIGO/OPTN) at the center.
    • No explicit accreditation or case-volume requirements are listed in this policy.

    Post-Transplant Services and Global Procedure Coverage

    Comprehensive transplant service — global and related procedure codes
    Global comprehensive transplant codeS2152 — Solid organ(s) procurement, transplantation, and related complications; comprehensive global code covering procurement, transplantation, hospitalization, outpatient follow-up, drugs, supplies, and defined pre/posttransplant care
    Donor nephrectomy (cadaver)50300 — Donor nephrectomy (including cold preservation); from cadaver donor, unilateral or bilateral
    Donor nephrectomy (living donor, open)50320 — Donor nephrectomy (including cold preservation); open, from living donor
    Renal allotransplantation (implantation)50360 — Renal allotransplantation, implantation of graft; without recipient nephrectomy; 50365 — with recipient nephrectomy

    Background and Rationale

    Kidney transplantation is the preferred treatment for pediatric patients with advanced chronic kidney disease or end‑stage renal disease because it improves survival, quality of life, and supports normal growth and development. When feasible, preemptive transplantation (often from a living donor) is preferred. Candidate evaluation should be multidisciplinary and follow KDIGO and OPTN guidance, with efforts to identify the cause of ESRD and to optimize the child’s medical status prior to transplantation.

    Policy Summary
    PayerAmbetter Nevada
    PolicyPediatric Kidney Transplant Coverage Criteria
    Policy CodePolicy CP.MP.246
    Change TypeCriteria revision (GFR thresholdscontraindication clarifications)
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and submit clinical documentation demonstrating ESRD (GFR < 15) or CKD stage 4 (GFR < 30 if expected to reach ESRD) and absence of listed contraindications.
    SourceLink
    On This Page
    Transplant Coverage CriteriaCandidate Selection and EligibilityContraindications and ExclusionsPre-Transplant Evaluation RequirementsProvider Actions and Prior AuthorizationCoding and Billing References (Informational)Definitions and ThresholdsCenter and Program RequirementsPost-Transplant Services and Global Procedure CoverageBackground and Rationale
    See individual items for specifics

    Documentation should demonstrate remediation or absence of these contraindications prior to approval.

    HIV-specific documentation: For HIV-positive candidates, document CD4 > 200 cells/mm3, absence of active AIDS-defining opportunistic infection, and that the member is receiving effective ART.CD4 > 200 cells/mm3

    If these are not met, transplant is contraindicated until criteria are satisfied.

    Required clinical documentation and HIV-specific requirements

    Provide clinical documentation that demonstrates advanced renal disease per policy thresholds and absence of listed contraindications; for HIV-positive candidates include CD4 > 200, no active AIDS-defining opportunistic infection, and evidence of current effective ART.

    • Document ESRD with GFR < 15 mL/min/1.73m2 or CKD stage 4 with GFR < 30 mL/min/1.73m2 expected to progress to ESRD.
    • Document absence of listed contraindications (see policy).
    • For HIV: CD4 > 200 cells/mm3, absence of active AIDS-defining opportunistic infection, and current effective antiretroviral therapy.
    Denial Risk

    Active or unremediable contraindications can cause denial

    Presence of any listed active or unremediable contraindication may render transplant not medically necessary and can lead to denial until resolved or managed per policy.

    • Active untreated infection (except hepatitis C) excludes coverage until treated.
    • Active malignancy with high recurrence/death risk, recent stroke/TIA within policy time windows, active symptomatic cardiac or peripheral arterial disease without appropriate evaluation/management, inability to adhere to required regimen, active substance use disorder, decompensated cirrhosis (unless candidate for combined liver-kidney), and elevated anti-GBM antibodies are examples of contraindications that may cause denial.
    Patients with GFR above 30 who are rapidly progressing toward ESRD should be referred for evaluation